FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2574362743> ?p ?o ?g. }

• W2574362743 endingPage "16" @default.
• W2574362743 startingPage "16" @default.
• W2574362743 abstract "Abstract High-risk Non-Hodgkin lymphoma (NHL) in elderly patients (&gt; 60 yrs) is associated with a relatively low complete response (CR) rate and a poor overall survival (OS). Previous studies have shown that addition of Rituximab to standard CHOP chemotherapy may improve CR and/or OS. A similar improvement has been shown for intensification of CHOP from 21 day intervals to 14 day intervals. The Dutch HOVON group and the Nordic lymphoma group have performed a multi-center, randomized phase III trial to compare 8 cycles of intensified CHOP (CHOP14) with the same regimen plus 6 administrations of Rituximab in previously untreated elderly patients with intermediate or high-risk NHL. Inclusion criteria were diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma grade III; intermediate or high-risk NHL according to age adjusted IPI score; CD20-positive NHL; age 65 yrs or higher. The target number was 400 patients to be accrued in 5 years based on an expected increase in event-free survival with hazard ratio HR=0.70. Aplanned interim analysis was performed after inclusion of 250 patients, restricted to 211 patients included from 1st September 2001 to 1st October 2004. Forty patients had to be excluded because of lack of treatment and evaluation data, leaving 171 patients for the analysis. The median time off protocol treatment was 119 days (range 4–468 days). The median age was 73 years (range 62–88 years). There was no difference between the two treatment arms regarding histology, age, WHO classification of NHL, age-adjusted IPI score, Ann Arbor stage, WHO performance status and serum LDH. There was no significant difference of toxicity or CR between the two treatment arms. However, a highly significant difference was observed for event-free survival and overall survival in favor of the treatment arm with CHOP plus Rituximab. Based on this interim analysis, the randomization was halted and patients in the control arm were further treated with CHOP plus Rituximab. Since the outcome of the interim analysis could be biased due to incomplete data, a final decision to stop the trial awaits a new analysis which is planned for 26th August 2005 after collection of missing or incomplete data. If the new analysis confirms the results of the interim analysis, i.e. that Rituximab significantly improves the outcome of treatment in elderly patients with intermediate or high-risk NHL, even when an intensified CHOP regimen is used, the study will be closed and outcomes will be presented." @default.
• W2574362743 created "2017-01-26" @default.
• W2574362743 creator A5000956898 @default.
• W2574362743 creator A5002972322 @default.
• W2574362743 creator A5006966014 @default.
• W2574362743 creator A5028760009 @default.
• W2574362743 creator A5037999437 @default.
• W2574362743 creator A5042572051 @default.
• W2574362743 creator A5043494139 @default.
• W2574362743 creator A5044368276 @default.
• W2574362743 creator A5071537090 @default.
• W2574362743 creator A5088720489 @default.
• W2574362743 date "2005-11-16" @default.
• W2574362743 modified "2023-09-30" @default.
• W2574362743 title "Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups." @default.
• W2574362743 doi "https://doi.org/10.1182/blood.v106.11.16.16" @default.
• W2574362743 hasPublicationYear "2005" @default.
• W2574362743 type Work @default.
• W2574362743 sameAs 2574362743 @default.
• W2574362743 citedByCount "20" @default.
• W2574362743 countsByYear W25743627432015 @default.
• W2574362743 crossrefType "journal-article" @default.
• W2574362743 hasAuthorship W2574362743A5000956898 @default.
• W2574362743 hasAuthorship W2574362743A5002972322 @default.
• W2574362743 hasAuthorship W2574362743A5006966014 @default.
• W2574362743 hasAuthorship W2574362743A5028760009 @default.
• W2574362743 hasAuthorship W2574362743A5037999437 @default.
• W2574362743 hasAuthorship W2574362743A5042572051 @default.
• W2574362743 hasAuthorship W2574362743A5043494139 @default.
• W2574362743 hasAuthorship W2574362743A5044368276 @default.
• W2574362743 hasAuthorship W2574362743A5071537090 @default.
• W2574362743 hasAuthorship W2574362743A5088720489 @default.
• W2574362743 hasConcept C126322002 @default.
• W2574362743 hasConcept C141071460 @default.
• W2574362743 hasConcept C168563851 @default.
• W2574362743 hasConcept C207103383 @default.
• W2574362743 hasConcept C2776694085 @default.
• W2574362743 hasConcept C2777058707 @default.
• W2574362743 hasConcept C2777525834 @default.
• W2574362743 hasConcept C2778336483 @default.
• W2574362743 hasConcept C2778559949 @default.
• W2574362743 hasConcept C2779338263 @default.
• W2574362743 hasConcept C2779725641 @default.
• W2574362743 hasConcept C2780653079 @default.
• W2574362743 hasConcept C2781413609 @default.
• W2574362743 hasConcept C44249647 @default.
• W2574362743 hasConcept C61943457 @default.
• W2574362743 hasConcept C71924100 @default.
• W2574362743 hasConcept C90924648 @default.
• W2574362743 hasConceptScore W2574362743C126322002 @default.
• W2574362743 hasConceptScore W2574362743C141071460 @default.
• W2574362743 hasConceptScore W2574362743C168563851 @default.
• W2574362743 hasConceptScore W2574362743C207103383 @default.
• W2574362743 hasConceptScore W2574362743C2776694085 @default.
• W2574362743 hasConceptScore W2574362743C2777058707 @default.
• W2574362743 hasConceptScore W2574362743C2777525834 @default.
• W2574362743 hasConceptScore W2574362743C2778336483 @default.
• W2574362743 hasConceptScore W2574362743C2778559949 @default.
• W2574362743 hasConceptScore W2574362743C2779338263 @default.
• W2574362743 hasConceptScore W2574362743C2779725641 @default.
• W2574362743 hasConceptScore W2574362743C2780653079 @default.
• W2574362743 hasConceptScore W2574362743C2781413609 @default.
• W2574362743 hasConceptScore W2574362743C44249647 @default.
• W2574362743 hasConceptScore W2574362743C61943457 @default.
• W2574362743 hasConceptScore W2574362743C71924100 @default.
• W2574362743 hasConceptScore W2574362743C90924648 @default.
• W2574362743 hasIssue "11" @default.
• W2574362743 hasLocation W25743627431 @default.
• W2574362743 hasOpenAccess W2574362743 @default.
• W2574362743 hasPrimaryLocation W25743627431 @default.
• W2574362743 hasRelatedWork W1970884884 @default.
• W2574362743 hasRelatedWork W2247122458 @default.
• W2574362743 hasRelatedWork W2528175579 @default.
• W2574362743 hasRelatedWork W2562269384 @default.
• W2574362743 hasRelatedWork W2575086544 @default.
• W2574362743 hasRelatedWork W2580098189 @default.
• W2574362743 hasRelatedWork W2979864420 @default.
• W2574362743 hasRelatedWork W2979885356 @default.
• W2574362743 hasRelatedWork W2980299611 @default.
• W2574362743 hasRelatedWork W3031860663 @default.
• W2574362743 hasVolume "106" @default.
• W2574362743 isParatext "false" @default.
• W2574362743 isRetracted "false" @default.
• W2574362743 magId "2574362743" @default.
• W2574362743 workType "article" @default.